Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA/Kaiser Study Questions Merck's Vioxx Cardiovascular Safety

This article was originally published in The Pink Sheet Daily

Executive Summary

Vioxx at doses greater than 25 mg/day is associated with increased risk of acute myocardial infarction and sudden cardiac death, study says. Pfizer's Celebrex had a lower risk of cardiovascular events, the study finds.
Advertisement

Related Content

Celebrex Cardiovascular Safety Supported In FDA/Kaiser Study
FDA Memo Discussed Pulling Vioxx Based On HMO Study
Celebrex Cardiovascular Safety Supported In FDA/Kaiser Study
FDA Expands Data Mining Contract With Premier
Merck Vioxx Communications With FDA Questioned By Senate Finance Cmte.
FDA Sought To Suppress Vioxx Safety Data, Sen. Grassley Says
Vioxx Withdrawal Could Have Impact On Post-Marketing Surveillance Methods
FDA Has One Month To Mull Approval Of Merck's Arcoxia Following Vioxx Withdrawal
FDA Has One Month To Mull Approval Of Merck's Arcoxia Following Vioxx Withdrawal
Arcoxia "Coming Soon" Journal Ads Running As User Fee Date Approaches

Topics

Advertisement
UsernamePublicRestriction

Register

PS060390

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel